A central analysis of real-world elranatamab-bcmm (Elrexfio) showed that it had numerically shorter progression-free survival (PFS) but higher response rates compared with real-world teclistamab-cqyv (Tecvayli) in patients with…
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
